Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC28-E for diabetic macular edema – phase 2 China trial
CTR20202526Phase 2Completed
- Sponsor
- Rongchang Pharmaceuticals
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of eflimrufusp alfa in diabetic macular edema (DME), sponsored by Rongchang Pharmaceuticals. Started Dec 2020; status: completed.
02
Drugs
eflimrufusp alfa
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20202526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202526.